Drug details:
Molecular formula: C₂₁H₃₃N₉

Standard name: (5R,6R)-5,6-bis[(4-tert-butyltriazol-1-yl)methyl]-4,5,6,7-tetrahydro-1H-benzimidazol-2-amine

Curated SMILES: CC(C)(C)C1=CN(C[C@@H]2CC3=C(C[C@H]2CN2C=C(C(C)(C)C)N=N2)NC(N)=N3)N=N1

Evidence for compound's anti-virulence activity:

Acinetobacter
Related VFcategory: Biofilm
Target: Not determined
Drug effect: Inhibits biofilm formation.
Max phase: Preclinical (in vitro)
Publication:
Huigens RW 3rd, et al., 2009. Inhibition of Acinetobacter baumannii, Staphylococcus aureus and Pseudomonas aeruginosa biofilm formation with a class of TAGE-triazole conjugates. Org Biomol Chem 7(4):794-802.

Staphylococcus
Related VFcategory: Biofilm
Target: Not determined
Drug effect: Inhibits biofilm formation.
Max phase: Preclinical (in vitro)
Publication:
Huigens RW 3rd, et al., 2009. Inhibition of Acinetobacter baumannii, Staphylococcus aureus and Pseudomonas aeruginosa biofilm formation with a class of TAGE-triazole conjugates. Org Biomol Chem 7(4):794-802.